CBS 2019
CBSMD教育中心
English

推荐文献

科研文章

荐读文献

Variation in Revascularization Practice and Outcomes in Asymptomatic Stable Ischemic Heart Disease The spectrum of chronic coronary syndromes: genetics, imaging, and management after PCI and CABG Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction 10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) With Validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study) Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations Management of Patients With NSTE-ACS: A Comparison of the Recent AHA/ACC and ESC Guidelines Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents 2-Year Clinical Outcomes: From the BIONICS and NIREUS Trials State of the Art in Noninvasive Imaging of Ischemic Heart Disease and Coronary Microvascular Dysfunction in Women: Indications, Performance, and Limitations The year in cardiovascular medicine 2020: interventional cardiology Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation

Guideline2014 Jul 1;63(25 Pt B):2889-934.

JOURNAL:J Am Coll Cardiol. Article Link

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Stone NJ, Robinson JG, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Keywords: ACC/AHA Practice Guideline; biomarkers, pharmacological; cardiovascular disease; cholesterol; diabetes mellitus; drug therapy; hydroxymethylglutaryl-CoA reductase inhibitors/statins; hypercholesterolemia; lipids; patient compliance; primary prevention; risk assessment; risk reduction behavior; secondary prevention

Full Text PDF